机构地区:[1]华北理工大学附属唐山市工人医院神经内科,河北省唐山市063000 [2]首都医科大学附属北京天坛医院卒中临床试验与临床研究中心 [3]河北医科大学第二医院神经内科
出 处:《中华神经科杂志》2018年第4期268-274,共7页Chinese Journal of Neurology
基 金:“十一五”国家科技支撑计划(2006BAl01A11);“十二五”国家科技支撑计划(2011BAl08802);2016年北京市科学技术委员会“首都临床特色应用研究”专项课题(Z161100000516079);河北省卫计委2017年度医学科学研究重点课题计划项目(20170097)
摘 要:目的探讨估算肾小球滤过率(estimated glomerular filtration rate,eGFR)对急性缺血性卒中(acuteischemicstroke,AIS)患者重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓后临床结局的预测价值。方法连续收集于2006年1-9月唐山工人医院神经内科因急性缺血性卒中行rt-PA静脉溶栓的患者,按照eGFR正常与否分为eGFR正常组(eGFRt〉90ml·min^-1·1.73m^-2)与eGFR下降组(eGFR〈90ml·min^-1-1.73m12),观察比较两组患者结局指标发生率的差异。结局指标包括症状性脑出血、溶栓后24h及7d早期神经功能恶化、7d内及90d内死亡、90d预后良好,运用单因素及多因素Logistic回归模型计算OR值及95%CI。结果本研究共纳入258例患者,其中eGFR正常组182例,eGFR下降组76例,校正两组间基线不均衡的变量后,多因素Logistic回归分析显示,eGFR下降组较eGFR正常组症状性脑出血的发生率增高[13.2%(10/76)和3.3%(6/182),OR=3.859,95%C11.313~11.341],24h早期神经功能恶化风险增高[21.1%(16/76)和8.2%(15/182),OR=2.958,95%CI1.347~6.495],7d早期神经功能恶化风险增高[32.9%(25/76)和12.6%(23/182),OR=3.129,95%CI1.555~6.293],7d内病死率增高[22.4%(17/76)和6.0%(11/182),OR=4.079,95%CI1.588—10.477],90d内病死率增高[23.7%(18/76)和9.9%(18/182),OR=2.457,95%CI1.050~5.749],90d预后良好率降低[22.4%(17/76)和43.4%(79/182),OR=0.435,95%C10.229~0.824]。结论eGFR下降可能会增加rt-PA静脉溶栓后症状性脑出血、早期神经功能恶化及死亡风险,且降低90d预后良好率。临床试验注册:中国临床试验注册中心。Objective To explore the association between estimated glomerular fihration rate (eGFR) and prognosis of acute ischemic stroke (AIS) patients who were treated by intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA). Methods We consecutively screened AIS patients who were treated by intravenous thrombolysis with rt-PA from January 2006 to September 2016 in Tangshan Gongren Hospital. According to eGFR value of patients at admission, the eligible patients were divided into two groups: normal eGFR group (eGFR≥90 ml · min^-l· 1.73 m^-2) and decreased eGFR group (eGFR 〈 90 ml·min^-1 · 1.73 m^-2). The incidence of symptomatic intracerebral hemorrhage (SICH), early neurological deterioration (END) at 24 hours and seven days after thrombolysis, mortality within seven days and 90 days, and excellent recovery at 90 days were compared between the two groups. The OR with 95% C! and the adjusted OR with 95% CI were analyzed by univariate and multivariate Logistic regression models. Results A total of 258 patients were enrolled, including 182 cases in the normal eGFR group and 76 cases in the decreased eGFR group. After adjusting for the potential confounders, multivariate Logistic regression analysis showed that the rates of SICH ( 13.2% (10/76) vs 3.3% (6/182) , OR = 3. 859, 95% CI 1. 313 - 11. 341 ), END at 24 hours (21.1% (16/76) vs 8.2% (15/182), OR =2. 958, 95% CI 1.347 -6.495) and seven days (32.9% (25/76) vs 12.6%(23/182), 0R=3.129, 95% CI 1.555- 6. 293), mortality within seven days (22.4% (17/76) vs 6. 0% ( 11/182), OR=4. 079, 95% CI 1. 588 - 10. 477) and 90 days (23.7% (18/76) vs 9.9% ( 18/182), OR = 2. 457, 95% CI 1. 050 - 5. 749) were higher in the decreased eGFR group than in the normal eGFR group. On the other hand, the ehance of excellent recovery at 90 days (22.4% (17/76) vs 43.4% (79/182), OR = 0. 435, 95% CI O. 229 - O. 824) was less in the decreased eGFR group than in the nor
关 键 词:脑缺血 卒中 血栓溶解疗法 肾小球滤过率 组织型纤溶酶原激活物
分 类 号:R743.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...